New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNE;CAT;HES;BBY;KERX;FURX;JOSB;ROP;MW;RPRX;BBBY From The Last 14 Days
Check below for free stories on SNE;CAT;HES;BBY;KERX;FURX;JOSB;ROP;MW;RPRX;BBBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
July 18, 2014
06:06 EDTSNEXbox Live, PlayStation Network users report connectivity issues, Re/code says
Xbox Live (MSFT) and PlayStation Network (SNE) users yesterday reported problems with connecting to their online services, Re/code reports. The connectivity issues could be connected to the start of a beta period for the upcoming Bungie-Activision (ATVI) game Destiny, the publication says. Reference Link
06:06 EDTSNESony confirms PlayStation4 is top selling next-gen consol in June for U.S.
Subscribe for More Information
July 17, 2014
10:41 EDTBBBYBed Bath & Beyond announces $1.1B accelerated share repurchase
Subscribe for More Information
10:00 EDTBBBYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 16, 2014
17:25 EDTBBBYBed Bath & Beyond initiated with a Neutral at Nomura
Subscribe for More Information
13:28 EDTRPRXRepros Therapeutics trial endpoints should be achieved, says Piper Jaffray
Piper Jaffray believes the endpoints selected for the Androxal Phase 3 studies for the treatment of secondary hypogonadism should be "readily achieved." Piper views the company's dialogue with the FDA as "very constructive" and reiterates an Overweight rating on Repros with a $26 price target.
12:22 EDTBBYBest Buy calls active on speculation of an activist investor stake
Subscribe for More Information
10:24 EDTBBYRumor: Best Buy moves up on speculation of an activist investor stake
Subscribe for More Information
09:26 EDTRPRXRepros Therapeutics announces FDA confirmation of endpoints for Androxal
Repros Therapeutics announced it has received additional guidance from the FDA regarding primary endpoints for the two studies, ZA-304 and ZA-305, that it is currently conducting comparing Androxal to the leading approved testosterone gel and placebo. The FDA proposed three co-primary endpoints: Percentage change from baseline in sperm concentration comparing Androxal to the leading U.S. testosterone replacement therapy; proportion of men obtaining a testosterone in the normal range; percentage of men that exhibit sperm greater than or equal to 10M/mL at the end of 16 weeks of dosing and testosterone in the normal range, comparing Androxal to a testosterone gel as well as comparing Androxal to placebo. The primary endpoints and statistical analysis plan outlined for ZA-304 and ZA-305 below are being modified to comply with the FDA suggestions. The company believes the two studies are adequately powered to meet these endpoints.
06:14 EDTSNEABI Research: More than 2B smartphones to ship in 2018, DigiTimes says
Subscribe for More Information
July 15, 2014
10:28 EDTKERXHigh option volume stocks
High option volume stocks: TRGT ALB UUP ADHD ROC WWW CTRL KERX IMGN NI
06:30 EDTSNEDOJ investigating music publishing, possible price coordination, WSJ reports
Subscribe for More Information
06:11 EDTSNESamsung, HiSilicon to sell more handset solutions to vendors, DigiTimes says
Subscribe for More Information
06:04 EDTBBBYStocks with implied volatility below IV index mean; BBBY SHPG
Subscribe for More Information
05:42 EDTBBBYBed Bath & Beyond announces planned $1.1B accelerated share repurchase
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use